Literature DB >> 15290168

Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.

Diego Marchesoni1, L Driul, B Mozzanega, G B Nardelli, A Parenti.   

Abstract

CASE REPORT: In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer. She came to our department because of vaginal bleeding 2 years after the end of tamoxifen treatment. TREATMENT: She underwent hysteroscopy and a D and C. A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps. OUTCOME: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic. Two years after surgery the patient is disease free, which is consistent with the evaluation of the surgical specimen, but unusual in poorly differentiated neoplasms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290168     DOI: 10.1007/s00404-004-0668-0

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  2 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Diagn Pathol       Date:  2008-02-08       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.